No significant co-alterations were found in gynecologic cancer samples.<h4>Conclusions</h4>ESR1 alterations were most frequent in HR + /HER2- BC samples and missense mutations were more frequent in metastatic samples, consistent with their role in ET resistance and disease progression. This evidence concerns the gene ESR1 and female reproductive organ cancer.